SARAH DEBOOR: Open Payments
NPI 1780126524 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,347 in 87 payments from 15 companies in 2025. Trend: 2023 $1,468 · 2024 $1,482 · 2025 $2,347
Food & beverage: $2,347
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $585 |
| Janssen Biotech, Inc. | 16 | $335 |
| Gilead Sciences, Inc. | 3 | $270 |
| Madrigal Pharmaceuticals | 5 | $228 |
| Phathom Pharmaceuticals, Inc. | 7 | $179 |
| GENZYME CORPORATION | 4 | $173 |
| Aimmune Therapeutics, Inc. | 4 | $164 |
| Novo Nordisk Inc | 1 | $118 |
| Ipsen Biopharmaceuticals, Inc | 3 | $71 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $70 |
Products named: TREMFYA, RINVOQ, REZDIFFRA, DUPIXENT, VOQUEZNA, SKYRIZI, ZENPEP, Livdelzi.
Industry payments across NV — which companies pay providers there.
